Literature DB >> 9531578

Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.

V Ollivier1, S Bentolila, J Chabbat, J Hakim, D de Prost.   

Abstract

The transmembrane protein tissue factor (TF) is the cell surface receptor for coagulation factor VII (FVII) and activated factor VII (FVIIa). Recently, TF has been identified as a regulator of angiogenesis, tumor growth, and metastasis. This study was designed to link the binding of FVII(a) to its receptor, TF, with the subsequent triggering of angiogenesis through vascular endothelial growth factor (VEGF) production by human lung fibroblasts. We report that incubation of fibroblasts, which express constitutive surface TF, with FVII(a) induces VEGF synthesis. FVII(a)-induced VEGF secretion, assessed by a specific enzyme-linked immunosorbent assay, was time- and concentration-dependent. VEGF secretion was maximal after 24 hours of incubation of the cells with 100 nmol/L FVII(a) and represented a threefold induction of the basal VEGF level. Reverse transcriptase-polymerase chain reaction analysis of VEGF detected three mRNA species of 180, 312, and 384 bp corresponding, respectively, to VEGF121, VEGF165, and VEGF189. A 2.5- to 3.5-fold increase was observed for the 180- and 312-bp transcripts at 12 and 24 hours, respectively. FVII(a)-dependent VEGF production was inhibited by a pool of antibodies against TF, pointing to the involvement of this receptor. On specific active-site inhibition with dansyl-glutamyl-glycinyl-arginyl chloromethyl ketone, FVIIa lost 70% of its capacity to elicit VEGF production. Consistent with this, the native form (zymogen) of FVII only had a 1.8-fold stimulating effect. Protein tyrosine kinase and protein kinase C are involved in signal transduction leading to VEGF production, as shown by the inhibitory effects of genistein and GF 109203X. The results of this study indicate that TF is essential for VIIa-induced VEGF production by human fibroblasts and that its role is mainly linked to the proteolytic activity of the TF-VIIa complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

Authors:  S D Konduri; A Tasiou; N Chandrasekar; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Early wound healing exhibits cytokine surge without evidence of hypoxia.

Authors:  Z A Haroon; J A Raleigh; C S Greenberg; M W Dewhirst
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Methylation of TFPI-2 is an early event of esophageal carcinogenesis.

Authors:  Yan Jia; Yunsheng Yang; Malcolm V Brock; Baoping Cao; Qimin Zhan; Yazhuo Li; Yuanzi Yu; James G Herman; Mingzhou Guo
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

4.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.

Authors:  S S Lakka; S D Konduri; S Mohanam; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.

Authors:  E Camerer; W Huang; S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation.

Authors:  J Erlich; G C Parry; C Fearns; M Muller; P Carmeliet; T Luther; N Mackman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 7.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

8.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.

Authors:  Joseph S Palumbo; Kathryn E Talmage; Jessica V Massari; Christine M La Jeunesse; Matthew J Flick; Keith W Kombrinck; Zhiwei Hu; Kelley A Barney; Jay L Degen
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

9.  Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Meena Gujrati; Ian McCutcheon; Dzung H Dinh; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

10.  Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis.

Authors:  Hao-Lan He; Ji-Bin Zhang; Qian Li
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.